肥胖静脉血栓栓塞症患者低分子肝素治疗剂量比较(RIETE登记研究)
RIETE登记研究纳入2846例体重>100 kg的静脉血栓栓塞症患者,比较低分子肝素封顶剂量(每日18000 IU)与非封顶剂量(每日>18000 IU)的复合结局(VTE复发、大出血或死亡)。封顶剂量组复合结局发生率显著低于非封顶剂量组(比值比0.16,95%CI 0.04-0.68)。
要点
- 体重>100 kg的VTE患者中,16%使用封顶剂量低分子肝素(每日18000 IU)。
- 封顶剂量组复合结局(VTE复发、大出血或死亡)比值比为0.16(95%CI 0.04-0.68)。
- 作者认为封顶剂量低分子肝素可作为按体重非封顶给药的替代选择。
核心结论
- 回顾性观察数据显示,肥胖VTE患者使用封顶剂量低分子肝素的复合事件率显著低于按体重非封顶剂量,作者认为封顶剂量是可接受的替代方案。
研究设计与样本
- 利用RIETE登记研究,回顾性观察性分析,纳入体重>100 kg的VTE患者2846例,其中454例(16%)接受封顶剂量低分子肝素(每日18000 IU),2392例接受非封顶剂量(每日>18000 IU)。
- 采用多变量logistic回归分析校正可能的混杂因素;封顶剂量组低分子肝素平均治疗14.8(标准差20.6)天,非封顶剂量组14.3(标准差32.3)天。
主要发现
- 31例(1.9%)发生VTE复发,38例(1.3%)发生出血事件,65例(2.3%)死亡,122例(4.3%)发生至少1项复合结局。
- 未校正分析显示封顶剂量与复合结局减少相关(率比0.22,95%CI 0.04-0.75)。
- 多变量分析证实封顶剂量组复合结局发生率显著更低(比值比0.16,95%CI 0.04-0.68)。
临床怎么用
- 作者认为,鉴于VTE复发、大出血和全因死亡的复合事件率显著更低,封顶剂量低分子肝素可作为按体重非封顶剂量的可接受替代方案。
局限性
- 原文为回顾性观察性数据,作者据此提出封顶剂量为可接受替代方案的结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because of the absence of comparative evidence, current guidelines and product monographs diverge in the dosing of low-molecular-weight heparin (LMWH) for obese patients with venous thromboembolism (VTE). We used the RIETE registry to compare the primary composite outcomes (VTE recurrence, major bleeding, or death) in patients with VTE who weighed >100 kg during LMWH therapy with capped doses of LMWH (18 000 IU/d) vs uncapped doses (>18 000 IU/d). Multivariable logistic regression analysis was used to account for possible confounders. A total of 2846 patients who weighed >100 kg were included: 454 (16%) received capped doses of LMWH, and the remaining 2392 received uncapped doses. Mean (standard deviation) LMWH treatment duration was 14.8 (20.6) and 14.3 (32.3) days, respectively. Thirty-one patients (1.9%) had VTE recurrences, 38 (1.3%) had bleeding episodes, 65 (2.3%) died, and 122 (4.3%) had at least 1 of the composite outcomes. Unadjusted outcome rates revealed that capped dosing was associated with a decrease in the composite outcome (rate ratio, 0.22; 95% confidence interval [CI], 0.04-0.75). Multivariable analysis confirmed that patients who received capped doses had significantly lower rates of the composite outcome (odds ratio, 0.16; 95% CI, 0.04-0.68) while receiving LMWH. These retrospective observational data suggest that capped dosing of LMWH is an acceptable alternative to uncapped dosing based on body weight, given the significantly lower composite event rate of VTE recurrence, major bleeding, and all-cause death.
引用
- Mirza R, Nieuwlaat R, López-Núñez JJ, et al. Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). Blood Adv. 2020. PMID: 32497167. doi:10.1182/bloodadvances.2019001373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。